By Week 16, 84% of adolescents achieved clear or almost clear skin, and 75% reached complete clearance by Week 24. From a clinical and quality-of-life standpoint, how meaningful is this level of early response in an adolescent population?

Given that many adolescents and their caregivers are hesitant about injectables, how does the availability of a once-daily oral IL-23 receptor antagonist like icotrokinra reshape the treatment paradigm for moderate-to-severe adolescent psoriasis?

Response rates improved between Week 16 and Week 24. What might this suggest about the time-to-peak efficacy for icotrokinra, and how could this influence patient and physician expectations for treatment response?

Adverse event rates were actually higher in the placebo group compared to icotrokinra (73% vs 50%). What do these safety results tell us about icotrokinra’s tolerability, and how does this influence its potential for long-term use starting at an early age?

Icotrokinra targets the IL-23 receptor rather than the cytokine itself. Can you explain the immunological significance of this distinction and whether this may lead to different therapeutic outcomes or safety signals?

Beyond skin clearance, adolescents with psoriasis often face emotional distress, school disruption, and comorbidities. How might an effective oral therapy influence broader health and psychosocial outcomes in this age group?

ICONIC-LEAD is the first registrational trial to study adolescents and adults simultaneously. What are the regulatory and clinical implications of this trial design in terms of speeding up access to therapy across age groups?

With multiple injectable IL-23 inhibitors already approved and used off-label in adolescents, what will icotrokinra’s differentiation hinge on—efficacy, convenience, safety, cost, or a combination thereof?